| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_676d70a55c2c2b61fa4c1cf128e7611c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-143 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-10 |
| filingDate |
2022-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efe9b945651941bc92546c151512dc52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebb93117fe4f40e90d431e2d840b652f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edc02725001d6ef52aa322fdbd3f5c58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce03b3b462aed224018fc21d18513280
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0c2904c8d4d2dcbc07144a4f618ff8a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59ebe84ea72004be058049c50935f510 |
| publicationDate |
2022-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114601938-A |
| titleOfInvention |
A fluorescence/NMR probe to guide accurate assessment of breast-conserving margins in breast cancer |
| abstract |
A fluorescence/nuclear magnetic probe for guiding accurate assessment of breast-conserving incision margins for breast cancer relates to the field of medical technology. The fluorescent/NMR probe is a Gd DTPA-HSA@ICG-bevacizumab near-infrared second-region fluorescence/magnetic resonance dual-modality molecular probe targeting VEGF-A. Preparation methods: 1) preparation of Gd DTPA-HSA@ICG nanoparticles; 2) preparation of Gd DTPA-HSA@ICG-bevacizumab near-infrared second region fluorescence/magnetic resonance dual-modality probe. The probe is used as a contrast agent to achieve preoperative MRI imaging of targeted breast cancer, evaluate tumor properties and formulate a breast-conserving surgery plan, and provide an important preoperative accurate imaging reference for intraoperative breast-conserving margin assessment; as a molecular The imaging probe is used for intraoperative near-infrared second-zone fluorescence surgical navigation, combined with preoperative MRI evaluation, to achieve accurate intraoperative tracking of breast tumor boundaries. |
| priorityDate |
2022-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |